Smoking in combination with antibodies to cyclic citrullinated peptides is associated with persistently high levels of survivin in early rheumatoid arthritis: A prospective cohort study

Arthritis Research and Therapy

Volumn 16, Issue 1, 2014, Pages

  Svensson, Björn ^a   Hafström, Ingiäld ^b   Erlandsson, Malin C ^c   Forslind, Kristina ^a,d   Bokarewa, Maria I ^c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d HELSINGBORG HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE; SURVIVIN; AUTOANTIBODY; AUTOANTIGEN; BIOLOGICAL MARKER; BIRC5 PROTEIN, HUMAN; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; INHIBITOR OF APOPTOSIS PROTEIN;

ADULT; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE COURSE; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; JOINT INJURY; JOINT RADIOGRAPHY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NOCICEPTION; OBSERVATIONAL STUDY; PHYSICAL DISABILITY; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REMISSION; REPRODUCIBILITY; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SHARP VAN DER HEIJDE SCORE; SMOKING; VISUAL ANALOG SCALE; ADVERSE EFFECTS; AGED; BLOOD; IMMUNOLOGY;

AGED; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOANTIGENS; BIOLOGICAL MARKERS; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; SMOKING;

EID: 84892425105     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4438     Document Type: Article

References (32)

1. Harrison BJ, Symmons DP, Brennan P, Barrett EM, Silman AJ. Natural remission in inflammatory polyarthritis: issues of definition and prediction. Br J Rheumatol 1996, 35:1096-1100. 10.1093/rheumatology/35.11.1096, 8948295.
2. van Aken J, van Dongen H, le Cessie S, Allaart CF, Breedveld FC, Huizinga TW. Comparison of long term outcome of patients with rheumatoid arthritis presenting with undifferentiated arthritis or with rheumatoid arthritis: an observational cohort study. Ann Rheum Dis 2006, 65:20-25. 10.1136/ard.2005.038471, 1797989, 15901632.
3. Freeston JE, Wakefield RJ, Conaghan PG, Hensor EMA, Stewart SP, Emery P. A diagnostic algorithm for persistence of very early inflammatory arthritis: the utility of power Doppler ultrasound when added to conventional assessment tools. Ann Rheum Dis 2010, 69:417-419. 10.1136/ard.2008.106658, 19359260.
4. de Rooy DP, Kälvesten J, Huizinga TW, van der Helm-van Mil AH. Loss of metacarpal bone density predicts RA development in recent-onset arthritis. Rheumatology (Oxford) 2012, 51:1037-1041. 10.1093/rheumatology/ker435, 22258391.
5. Karlson EW, Ding B, Keenan BT, Liao K, Costenbader KH, Klareskog L, Alfredsson L, Chibnik LB. Association of environmental and genetic factors and gene-environment interactions with risk of developing rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013, 65:1147-1156. 10.1002/acr.22005, 23495093.
6. Bukhari M, Thomson W, Naseem H, Bunn D, Silman A, Symmons D, Barton A. The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: results from the Norfolk Arthritis Register. Arthritis Rheum 2007, 56:2929-2935. 10.1002/art.22868, 2435419, 17763407.
7. Forslind K, Ahlmén M, Eberhardt K, Hafström I, Svensson B, BARFOT Study Group Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 2004, 63:1090-1095. 10.1136/ard.2003.014233, 1755129, 15308518, BARFOT Study Group.
8. Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 2004, 63:1085-1089. 10.1136/ard.2003.016808, 1755123, 15308517.
9. Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A, Nicaise-Roland P, Sibilia J, Combe B. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003, 62:120-126. 10.1136/ard.62.2.120, 1754441, 12525380.
10. Bokarewa M, Lindblad S, Bokarew D, Tarkowski A. Balance between survivin, a key member of the apoptosis inhibitor family, and its specific antibodies determines erosivity in rheumatoid arthritis. Arthritis Res Ther 2005, 7:R349-R358. 10.1186/ar1498, 1065333, 15743483.
11. Svensson B, Hafström I, Forslind K, Albertsson K, Tarkowski A, Bokarewa M. Increased expression of proto-oncogene survivin predicts joint destruction and persistent disease activity in early rheumatoid arthritis. Ann Med 2010, 42:45-54. 10.3109/07853890903376280, 20092399.
12. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008, 8:61-70. 10.1038/nrc2293, 18075512.
13. Baran M, Möllers LN, Andersson S, Jonsson IM, Ekwall AK, Bjersing J, Tarkowski A, Bokarewa M. Survivin is an essential mediator of arthritis interacting with urokinase signalling. J Cell Mol Med 2009, 13:3797-3808. 10.1111/j.1582-4934.2009.00721.x, 19298527.
14. Dharmapatni AA, Smith MD, Findlay DM, Holding CA, Evdokiou A, Ahern MJ, Weedon H, Chen P, Screaton G, Xu XN, Haynes DR. Elevated expression of caspase-3 inhibitors, survivin and xIAP correlates with low levels of apoptosis in active rheumatoid synovium. Arthritis Res Ther 2009, 11:R13. 10.1186/ar2603, 2688245, 19171073.
15. Smith MD, Weedon H, Papangelis V, Walker J, Roberts-Thomson PJ, Ahern MJ. Apoptosis in the rheumatoid arthritis synovial membrane: modulation by disease-modifying anti-rheumatic drug treatment. Rheumatology (Oxford) 2010, 49:862-875. 10.1093/rheumatology/kep467, 20147446.
16. Isgren A, Forslind K, Erlandsson M, Axelsson C, Andersson S, Lund A, Bokarewa M. High survivin levels predict poor clinical response to infliximab treatment in patients with rheumatoid arthritis. Semin Arthritis Rheum 2012, 41:652-657. 10.1016/j.semarthrit.2011.08.005, 22035627.
17. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
18. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48. 10.1002/art.1780380107, 7818570.
19. Prevoo ML, van Gestel AM, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Remission in a prospective study of patients with rheumatoid arthritis: American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 1996, 35:1101-1105. 10.1093/rheumatology/35.11.1101, 8948296.
20. Ekdahl C, Eberhardt K, Andersson SI, Svensson B. Assessing disability in patients with rheumatoid arthritis: use of a Swedish version of the Stanford Health Assessment Questionnaire. Scand J Rheumatol 1988, 17:263-271. 10.3109/03009748809098795, 3187457.
21. van der Heijde DM, van Leeuwen MA, van Riel PL, Koster AM, van 't Hof MA, van Rijswijk MH, van de Putte LB. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992, 35:26-34. 10.1002/art.1780350105, 1731813.
22. Li F, Ackermann EJ, Bennett CF, Rothermel AL, Plescia J, Tognin S, Villa A, Marchisio PC, Altieri DC. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1999, 1:461-466. 10.1038/70242, 10587640.
23. Santa Cruz Guindalini R, Mathias Machado MC, Garicochea B. Monitoring survivin expression in cancer: implications for prognosis and therapy. Mol Diagn Ther 2013, 17:331-342. 10.1007/s40291-013-0048-1, 23912862.
24. Grube M, Moritz S, Obermann EC, Rezvani K, Mackensen A, Andreesen R, Holler E. CD8+ T cells reactive to survivin antigen in patients with multiple myeloma. Clin Cancer Res 2007, 13:1053-1060. 10.1158/1078-0432.CCR-06-1722, 17289902.
25. Coughlin CM, Fleming MD, Carroll RG, Pawel BR, Hogarty MD, Shan X, Vance BA, Cohen JN, Jairaj S, Lord EM, Wexler MH, Danet-Desnoyers GA, Pinkus JL, Pinkus GS, Maris JM, Grupp SA, Vonderheide RH. Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma. J Clin Oncol 2006, 24:5725-5734. 10.1200/JCO.2005.05.3314, 17179106.
26. Khan S, Jutzy JM, Aspe JR, McGregor DW, Neidigh JW, Wall NR. Survivin is released from cancer cells via exosomes. Apoptosis 2011, 16:1-12. 10.1007/s10495-010-0534-4, 3174681, 20717727.
27. Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006, 10:1-229.
28. Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G, Rantapää-Dahlqvist S. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis 2006, 65:453-458. 10.1136/ard.2005.041376, 1798112, 16176994.
29. Klareskog L, Stolt P, Lundberg K, Källberg H, Bengtsson C, Grunewald J, Rönnelid J, Harris HE, Ulfgren AK, Rantapää-Dahlqvist S, Eklund A, Padyukov L, Alfredsson L. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006, 54:38-46. 10.1002/art.21575, 16385494.
30. Fawzy A, Gaafar R, Kasem F, Ali SS, Elshafei M, Eldeib M. Importance of serum levels of angiopoietin-2 and survivin biomarkers in non-small cell lung cancer. J Egypt Natl Canc Inst 2012, 24:41-45. 10.1016/j.jnci.2011.12.006, 23587231.
31. van den Broek M, Dirven L, de Vries-Bouwstra JK, Dehpoor AJ, Goekoop-Ruiterman YP, Gerards AH, Kerstens PJ, Huizinga TW, Lems W, Allaart CF. Rapid radiological progression in the first year of early rheumatoid arthritis is predictive of disability and joint damage progression during 8 years of follow-up. Ann Rheum Dis 2012, 71:1530-1533. 10.1136/annrheumdis-2011-201212, 22532630.
32. Wessels JA, van der Kooij SM, le Cessie S, Kievit W, Barerra P, Allaart CF, Huizinga TW, Guchelaar HJ. Pharmacogenetics Collaborative Research Group: a clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum 2007, 56:1765-1775. 10.1002/art.22640, 17530705.